Physician profile
Shodhan Patel
NPI 1457368680
$4,249.90
in general payments reported to CMS, 2019-2025
35 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $982 · 2021: $856 · 2022: $784 · 2023: $77.85 · 2024: $168 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $794.01 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $687.08 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $331.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.29 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $281.52 | 2019-2025 | |
| Lilly USA, LLC | $274.51 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $239.23 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $235.56 | 2019-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $154.54 | 2019-2022 | |
| Amarin Pharma, INC. | $105.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $78.09 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $66.31 | 2019-2025 | |
| Dexcom, INC. | $65.71 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $63.64 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $56.63 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $53.99 | 2022-2025 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $49.57 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $47.10 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $40.04 | 2019-2020 | |
| Exact Sciences Corporation | $39.52 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $33.55 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $28.47 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $28.06 | 2020 | |
| Abbvie INC. | $27.14 | 2021-2022 | |
| Amgen INC. | $26.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.39 | 2025 | Austedo Xr |
| Redhill Biopharma INC. | $14.46 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.71 | 2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $13.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.38 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.19 | 2019 | |
| Shield Therapeutics INC | $13.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.54 | 2019 | |
| Allergan, INC. | $11.60 | 2019 | |
| Circassia INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shodhan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.